Pressmeddelanden från 2cureX

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

2cureX AB (publ) publishes Interim Report for the Second Half of 2025 29 aug 2025 13:40

CEO Nathaniel Hutley presents a strategic update on 2cureX’s new Website Blog.21 aug 2025 16:10

2cureX AB (“2cureX”) hereby publishes the interim report for the first half year of 2025.11 jul 2025 21:10

Improved communication from 2cureX AB 02 jul 2025 13:19

Correction: CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025.01 jul 2025 14:25

2cureX AB is in the process of securing a strategic collaboration with PreComb Therapeutics AG.27 jun 2025 22:35

KOMMUNIKÉ FRÅN ÅRSSTÄMMAN I 2CUREX AB (PUBL)13 jun 2025 14:15

CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025.30 maj 2025 13:30

KALLELSE TILL ÅRSSTÄMMA I 2CUREX AB (publ).29 maj 2025 17:30

PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (PUBL)22 maj 2025 09:15

2cureX appoints Mangold Fondkommission AB as new Certified Adviser 20 maj 2025 10:00

2cureX Conducts First Direct-to-Patient IndiTreat® Test Under “Operation Twin Code” Strategy 15 maj 2025 17:20

2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap 14 apr 2025 12:00

EARLY NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ)27 feb 2025 13:00

2cureX publishes interim report for the second half year of 2024 20 jan 2025 16:00

2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE 10 jan 2025 16:00

Correction: 2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE 10 jan 2025 14:00

2CUREX APPOINTS MANGOLD CORPORATE FINANCE TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE 18 dec 2024 19:15

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)16 dec 2024 13:00

2cureX AB Announces the Appointment of Dan Honeywell as CEO, Ushering in a New Era of commercial expansion of breakthrough precision oncology products 29 nov 2024 15:00

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB 24 sep 2024 19:45

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)09 sep 2024 12:30

Invitation to 2cureX Webcast with Q&A on 24 September 2024 04 sep 2024 08:45

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB (PUBKL)22 aug 2024 13:00

2cureX publishes interim report for the first half year of 2024 12 jul 2024 18:00

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)01 jul 2024 17:35

KOMMUNIKÉ FRÅN ÅRSSTÄMMAN I 2CUREX AB (PUBL)28 jun 2024 15:00

PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (PUBL)26 jun 2024 16:15

EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)18 jun 2024 13:45

2CUREX APPOINTS OLE THASTRUP AS NEW CEO 18 jun 2024 00:05

Correction: 2CUREX AB ABORTS DELISTING AND ANNOUNCES DIRECTED SHARE ISSUE TO A PRIVATE INVESTMENT COMPANY AND SALE OF THE SUBSIDIARY 2CUREX A/S 17 jun 2024 23:45

2CUREX AB ABORTS DELISTING AND ANNOUNCES DIRECTED SHARE ISSUE TO A PRIVATE INVESTMENT COMPANY AND SALE OF THE SUBSIDIARY 2CUREX A/S 29 maj 2024 14:30

KALLELSE TILL ÅRSSTÄMMA I 2CUREX AB (PUBL)29 maj 2024 14:16

Correction: Revised Financial Calendar Announcement 29 maj 2024 14:10

Correction: Revised Financial Calendar Announcement 27 maj 2024 21:45

Revised Financial Calendar Announcement 07 maj 2024 10:35

2CUREX AB (PUBL) HAS DECIDED TO APPLY FOR A DELISTING OF ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET IN STOCKHOLM – EXPECTED LAST DAY OF TRADING BY END OF JUNE 16 mar 2024 17:00

2CUREX AB (PUBL) PROVIDES AN UPDATE ON ITS FINANCIAL POSITION AND CURRENT OPERATIONS 29 feb 2024 16:00

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)22 feb 2024 14:45

2CUREX PUBLISHES INTERIM REPORT FOR THE FOURTH QUARTER AND FULL YEAR OF 2023 AND FINANCIAL AND STRATEGIC OUTLOOK FOR 2024 12 feb 2024 14:00

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)04 jan 2024 08:30

2cureX announces changes to the Board of Directors.29 dec 2023 14:30

2cureX announces changes to the management 06 dec 2023 08:45

2cureX Receives Ethical Approval for Groundbreaking HIPEC Clinical Trial 23 nov 2023 08:30

2cureX publishes interim report for the third quarter of 2023 14 nov 2023 16:00

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMAN I 2CUREX AB (PUBL)10 nov 2023 08:45

IndiTreat® Image Uploader gets IVD CE-Mark 30 okt 2023 08:45

2cureX participated in “Knæk Cancer” panel discussion.26 okt 2023 18:30

Strategy update: Leapfrogging to the decentralization of IndiTreat® testing through full focus on automation 25 okt 2023 15:46

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)11 okt 2023 12:45

2cureX advances towards IVD-R compliance by securing a contract with a Notified Body 03 okt 2023 09:15

2cureX will be holding its Q3 2023 online presentation with a Q&A session on October 26, 2023 at 20.00 (CET).30 aug 2023 08:30

2cureX launches its first two IndiTreat® products CE-marked under the new IVD Regulation 24 aug 2023 08:30

2cureX publishes interim report for Q2 2023 05 jul 2023 08:30

Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET)25 maj 2023 18:30

Kommuniké från årsstämma i 2cureX AB 25 maj 2023 08:00

2cureX publishes interim report for the first quarter of 2023 11 maj 2023 08:50

Positive IndiTreat® trial results published in highly recognized scientific journal.27 apr 2023 15:30

Kallelse till årsstämma i 2cureX AB (publ)25 apr 2023 16:00

2cureX’s CEO Fernando Andreu purchases shares in the company 20 apr 2023 16:10

2cureX offentliggör årsredovisning för räkenskapsåret 2022 12 apr 2023 14:30

2cureX presents preliminary Q1 2023 commercial results.12 apr 2023 13:00

2cureX has received a grant from the Innovation Fund Denmark to support clinical development of a novel IndiTreat® product.10 apr 2023 08:30

Invitation to 2cureX Q1 update and Q&A session on April 12, 2023 at 20.00 (CET)06 apr 2023 08:30

2cureX strengthens its IndiTreat® automation project with a prestigious grant from the German Federal Ministry of Education and Research 23 mar 2023 08:30

2cureX announces launch of updated Specimen Collection Set 23 feb 2023 08:30

2cureX publishes interim report for the fourth quarter and full year of 2022 15 feb 2023 17:30

Invitation to 2cureX webcast on Year-End Report and latest news on February 23, 2023 10 feb 2023 11:50

Kommuniké från extra bolagsstämma i 2cureX AB 23 jan 2023 20:50

KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)19 jan 2023 11:45

2cureX announces final results regarding 2022 goals 20 dec 2022 08:30

2cureX reaches 2022 geographic rollout goal of 20 countries 24 nov 2022 08:00

2cureX publishes interim report for the third quarter and first nine months of 2022 22 nov 2022 17:30

Invitation to 2cureX webcast and conference call on November 24, 2022 14 nov 2022 08:30

2cureX discloses status of 2022 plans, goals for 2023 and its estimates of potential market development in the coming years 01 nov 2022 13:00

Invitation to 2cureX Strategy Deep-Dive 11 okt 2022 12:30

Independent market survey shows great demand for 2cureX product portfolio 06 okt 2022 12:15

Co-inventor of 2cureX patents awarded Nobel Prize in Chemistry 29 sep 2022 21:00

2cureX terminates liquidity provision service 19 sep 2022 08:30

Change of distribution partner in Portugal 01 sep 2022 08:30

2cureX expands distribution of IndiTreat® to Romania 25 aug 2022 08:30

2cureX offentliggör delårsrapport för det andra kvartalet och första halvåret 2022 08 aug 2022 14:30

Kommuniké från extra bolagsstämma i 2cureX 20 jul 2022 13:00

Kallelse till extra bolagsstämma i 2curex AB 01 jul 2022 08:45

Dr. Raphael Gruber joins 2cureX as new Medical Director 28 jun 2022 08:45

2cureX expands distribution of IndiTreat® to Israel 07 jun 2022 12:30

2cureX AB announces share purchase by the company’s Chairman of the Board of Directors and Executive Management 31 maj 2022 08:45

Strengthening the IndiTreat® distribution in North Europe 24 maj 2022 16:30

Kommuniké från årsstämma i 2cureX AB 24 maj 2022 12:22

2cureX offentliggör delårsrapport för det första kvartalet 2022 20 maj 2022 13:45

We invite you to join the 2cureX Q1 Report webcast and Q&A session at 15:00 on 24 May, 2022 17 maj 2022 08:45

Three IndiTreat® posters have been accepted at ESMO-GI 2022 12 maj 2022 12:00

2cureX AB nominerar Dr. Michael Schaefer till styrelsen 11 maj 2022 08:45

IGNITE update - Eight hospitals have been enrolled in the program 09 maj 2022 08:45

2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine 06 maj 2022 08:45

2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie 05 maj 2022 09:30

Redeye research interview with 2cureX CEO, Fernando Andreu 03 maj 2022 20:45

2cureX offentliggör årsredovisning för räkenskapsåret 2021 29 apr 2022 13:30

Rättelse: Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022 22 apr 2022 18:00

Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022